Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response
The Journal of Clinical Pharmacology · 2023-06 · 63 (S1)
DOI: 10.1002/jcph.2227 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 14.06.2023. Verfasst von Ahizechukwu C Eke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Biological Products. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Pregnancy is a unique physiological state that results in many changes in bodily function, including cellular, metabolic, and hormonal changes. These changes can have a significant impact on the way small‐molecule drugs and monoclonal antibodies (biologics) function and are metabolized, including efficacy, safety, potency, and adverse effects. In this article, we review the various physiologic changes that occur during pregnancy and their effects on drug and biologic metabolism, including changes in the coagulation, gastrointestinal, renal, endocrine, hepatic, respiratory, and cardiovascular systems. Additionally, we discuss how these changes can affect the processes of drug and biologic absorption, distribution, metabolism, and elimination (pharmacokinetics), and how drugs and biologics interact with biological systems, including mechanisms of drug action and effect (pharmacodynamics) during pregnancy, as well as the potential for drug‐induced toxicity and adverse effects in the mother and developing fetus. The article also examines the implications of these changes for the use of drugs and biologics during pregnancy, including consequences of suboptimal plasma drug concentrations, effect of pregnancy on the pharmacokinetics and pharmacodynamics of biologics, and the need for careful monitoring and individualized drug dosing. Overall, this article aims to provide a comprehensive understanding of the physiologic changes during pregnancy and their effects on drug and biologic metabolism to improve the safe and effective use of drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Obstetrics and Gynecology, Addis Ababa University College of Medicine, Addis Ababa, Ethiopia.
- Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
- United States Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
ORCID-Profile: Ahizechukwu C Eke
Förderung
- NICHD NIH HHS
Zitieren
APA
Eke, A. C., Gebreyohannes, R. D., Fernandes, M. F. S., & Pillai, V. C. (2023). Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response. The Journal of Clinical Pharmacology, 63(S1). https://doi.org/10.1002/jcph.2227
Vancouver
Eke AC, Gebreyohannes RD, Fernandes MFS, Pillai VC. Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response. The Journal of Clinical Pharmacology. 2023;63(S1). doi:10.1002/jcph.2227
BibTeX
@article{Eke2023,
author = {Eke, Ahizechukwu C and Gebreyohannes, Rahel D and Fernandes, Maria Fernanda Scantamburlo and Pillai, Venkateswaran C},
title = {Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
volume = {63},
number = {S1},
doi = {10.1002/jcph.2227}
}
EUVIMED